Clinical trials: Risperidone
Treatment Resistant Depression
Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST)
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects.
- Trial name
- SYNVEST (NCT06512220)
- Testing
- Psilocybin 25 mg, Risperidone 1 MG
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Centre for Addiction and Mental Health
Weight Gain, Autism Spectrum Disorder
Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
This study aims to compare two FDA approved medications (aripiprazole and risperidone) for the treatment of behavioral dysregulation in children with autism spectrum disorders.
- Conditions
- Weight Gain, Autism Spectrum Disorder, Medication Side Effect
- Trial name
- NCT04903353
- Testing
- Comparison of Risperidone and Aripiprazole
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Major Depression Moderate, Major Depression Severe
Shortened LSD Intervention for Major Depressive Disorder
The purpose of this study is to determine the safety and clinical effectiveness of a shortened lysergic acid diethylamide (LSD) experience.
- Conditions
- Major Depression Moderate, Major Depression Severe, Major Depression
- Trial name
- SLIM (NCT07503002)
- Testing
- LSD, Risperidone
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Schizophrenia
A Comparator Study of LY2140023 Versus Placebo in Schizophrenia Patients
An inpatient/outpatient study to see if LY2140023 is better than placebo in acutely ill patients with schizophrenia.
- Trial name
- NCT01086748
- Testing
- Risperidone, LY2140023
- Where
- 28 sites in United States, Croatia and 1 more
- Volunteers
- 1,134 people
- Sponsor
- Denovo Biopharma LLC
Schizophrenia
A Long-Term, Open-Label, Study on Schizophrenia
The primary purpose of the study is to help answer the following research questions: How LY 2140023 can be tolerated by patients with Schizophrenia compared to standard of care treatment in 52 weeks time period.
- Trial name
- NCT01129674
- Testing
- LY2140023, Olanzapine, Aripiprazole
- Where
- 81 sites in United States, Croatia and 7 more
- Volunteers
- 560 people
- Sponsor
- Denovo Biopharma LLC
Attention, Visual Perceptual Weakness
Result of tDCS in ASD Children With Comorbidities Like PANDAS, Rare Genetic Diseases or Autoimmune Disorders
Results of the application of 100 sessions of tDCS for 12 months in children between 6 and 11 years old with autism spectrum disorder with rare diseases, genetic problems or PANDAS
- Conditions
- Attention, Visual Perceptual Weakness, Social Behavior, Fluency Disorder
- Trial name
- tDCS&ASD (NCT06368726)
- Testing
- tDCS or Transcranial Direct Current Stimulation, Risperidone
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- Spanish Foundation for Neurometrics Development
Investigating the Importance of the Subjective Psychedelic Experience
Subjective Experience Following Psilocybin
The purpose of this study is to determine the importance of the acute subjective experience induced by psilocybin (the primary component of "magic mushrooms") in facilitating positive outcomes.
- Trial name
- SEP-1 (NCT06768944)
- Testing
- Psilocybin high-dose, Psilocybin low-dose, Risperidone 1 MG
- Where
- Canada
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose…
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension
- Trial name
- POPS or POP02 (NCT04278404)
- Testing
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Where
- 52 sites in United States, Canada
- Volunteers
- 5,000 people, healthy volunteers welcome
- Sponsor
- Duke University
Schizophenia Disorder
Biomarkers to Enhance Early Schizophrenia Treatment
This study is recruiting participants who are experiencing a first episode of psychosis and who have certain genetic factors that may make them respond better to certain medications that are used to treat people with psychosis.
- Trial name
- BEEST (NCT06969755)
- Testing
- aripiprazole, risperidone, clozapine
- Where
- 5 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- Northwell Health
Negative Symptoms of Schizophrenia
Study to Evaluate Efficacy and Safety of Roluperidone in Adult Subjects With Negative Symptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Relapse Rate of Roluperidone and Antipsychotic Medications
Evaluate the efficacy, as well as safety and pharmacokinetics, of Roluperidone in improving the negative symptoms of schizophrenia in adult subjects in Phase A of study, followed by Phase B of study to evaluate the relapse rate…
- Trial name
- NCT07565428
- Testing
- Roluperidone, risperidone, aripiprazole
- Where
- 13 sites in United States
- Volunteers
- 380 people
- Sponsor
- Minerva Neurosciences
Schizophrenia, Cognitive and Executive Dysfunction
A Pilot Study of Adjunctive Structured Supportive Psychotherapy in Schizophrenia
This pilot randomized controlled trial examined whether adding structured supportive psychotherapy to risperidone treatment is more effective than risperidone alone in improving cognitive function and reducing peripheral…
- Conditions
- Schizophrenia, Cognitive and Executive Dysfunction, Neuroinflammation
- Trial name
- PILOT-SSP-SCZ (NCT07671040)
- Testing
- Structured supportive psychotherapy, Risperidone, Unstructured Supportive Conversation
- Where
- Indonesia
- Volunteers
- 44 people
- Sponsor
- Hasanuddin University
Bipolar 1 Disorder
Risperidone vs Cariprazine in Acute Mania
Randomized, double-blind, parallel-group study comparing efficacy and safety of Risperidone versus Cariprazine in adults with acute manic episodes. Participants will receive oral study drug for 6 weeks.
- Trial name
- RCAM (NCT07665073)
- Testing
- Risperidone, Cariprazine
- Volunteers
- 50 people
- Sponsor
- Pakistan Institute of Medical Sciences
Schizophrenia, Schizoaffective Disorders
An Efficacy and Safety Study of Long-acting Risperidone in Participants With Schizophrenia or Schizoaffective Disorders Who Are Receiving Psychiatric Home Care Treatment
The purpose of this study is to evaluate the efficacy and safety of long-acting risperidone microspheres (small uniformly-sized spherical particles, of micrometer dimensions, frequently labeled with radioisotopes or various…
- Trial name
- NCT00526877
- Testing
- Risperidone
- Where
- Taiwan
- Volunteers
- 31 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Schizophrenia
Cognitive Behavioral Therapy Added to Risperidone for Schizophrenia
This study evaluated whether cognitive behavioral therapy (CBT), when added to risperidone treatment, improves cognitive function and serum brain-derived neurotrophic factor (BDNF) levels in patients with schizophrenia.
- Trial name
- CBT-BDNF-SCZ (NCT07609953)
- Testing
- Risperidone 4 to 6 mg/day, Cognitive Behavioral Therapy
- Where
- Indonesia
- Volunteers
- 42 people
- Sponsor
- Hasanuddin University
Patient With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology
Study Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach
The objective of this study is to respond to frequent requests from patients who wish to reduce or even stop their antipsychotic treatment once they have achieved clinical stability.
- Conditions
- Patient With Schizophrenia Spectrum Disorder, NLM Classification WM 203, Psychology:Schizophrenic Psychology, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- DREAMS-Phen (NCT07152184)
- Testing
- Use of antipsychotic treatment with marketing authorization at doses lower than those recommended: - Olanzapine - Zuclopenthixol - Risperidone - Pipotiazine palmitate / Pipotiazine - Quetiapine - Flup
- Volunteers
- 288 people
- Sponsor
- University Hospital, Strasbourg, France
Psychosis; Acute
Cerebellum-based Imaging Neural Markers for Antipsychotic Response
This study plans to collect 120 patients with first-episode psychosis. Participants will receive multimodal MRI scans (naturalistic fMRI, structural, diffusional) and comprehensive clinical assessments at baseline, and…
- Trial name
- CINEMA (NCT07483294)
- Testing
- risperidone, aripiprazole
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Northwell Health
Schizophrenia
Switching Medication to Treat Schizophrenia
This study will evaluate the effectiveness of switching medications in decreasing schizophrenia symptoms in individuals who are currently taking an antipsychotic medication for the treatment of schizophrenia.
- Trial name
- NCT00044655
- Testing
- Risperidone, Olanzapine, Ziprasidone
- Volunteers
- 219 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Schizophrenia Patients, Neuroinflammation
Effectiveness of Ashwagandha in Schizophrenia Patients on Risperidone
This study aims to evaluate the effectiveness of Ashwagandha (Withania somnifera) extract as an adjuvant therapy in patients with schizophrenia who are receiving risperidone.
- Trial name
- WSE-SCZ (NCT07575516)
- Testing
- Risperidone 4mg/day, Ashwagandha
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- Hasanuddin University
Schizophrenia, Schizoaffective Disorder
CLOZAPINE Response in Biotype-1
The CLOZAPINE study is designed as a multisite study across 5 sites and is a clinical trial, involving human participants who are prospectively assigned to an intervention.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar 1 Disorder
- Trial name
- NCT04580134
- Testing
- clozapine, risperidone
- Where
- 5 sites in United States
- Volunteers
- 524 people
- Sponsor
- University of Texas Southwestern Medical Center
Treatment-resistant Depression
Does Psilocybin Require Psychedelic Effects to Treat Depression?
Psilocybin, the chemical component of "magic mushrooms", has been administered with psychotherapy in several randomized clinical trials (RCTs) showing large and sustained antidepressant effects.
- Trial name
- PSI-RIS (NCT05710237)
- Testing
- Psilocybin 25 mg, Risperidone 1 MG
- Where
- Canada
- Volunteers
- 41 people
- Sponsor
- Centre for Addiction and Mental Health